25 Aug 2020 Governance

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.

Angela was responsible for driving through the merger with Leuka in November 2019, and is now leaving the charity in a strong position to build on the remarkable transformation she engineered.

She has been a valued Co CEO of the merged charity and a visionary sole CEO of the original charity. We thank her for her outstanding work on our behalf and wish her the very best in the future.

Related posts

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

8 September 2022

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…

An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care

10 November 2021

An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care

Leukaemia UK has joined with 50 other cancer charities in writing to the Prime Minister, Chancellor of the Exchequer and Secretary of State for Health and Social Care. We are calling on the Government to urgently deliver on commitments to improve cancer survival and care in the forthcoming Spending Review.

John Goldman Fellowships for 2023 now open

5 December 2022

John Goldman Fellowships for 2023 now open

Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2023, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.